EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access

Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials

Akhil Deepak Vatvani, Andree Kurniawan, Timotius Ivan Hariyanto iD

Annals of Pharmacotherapy · 2023

DOI: 10.1177/10600280231162243 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Annals of Pharmacotherapy, 2023. Verfasst von Akhil Deepak Vatvani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fluvoxamine may be beneficial for the management of coronavirus disease 2019 (Covid-19) because of its effect on the sigma-1 receptor. Available evidence from randomized clinical trials (RCTs) has shown conflicting results.

Objective

This study sought to analyze the efficacy and safety of fluvoxamine as an outpatient treatment for Covid-19.

Methods

Using specific keywords, we comprehensively go through the potential articles on PubMed, Scopus, Europe PMC, and ClinicalTrials.gov sources until February 1, 2023. We collected all published clinical trials on fluvoxamine and Covid-19. We were using Review Manager 5.4 to conduct statistical analysis.

Results

We include a total of 6 trials. Our pooled analysis revealed that fluvoxamine did not offer any significant benefit when compared with placebo in reducing the risk of clinical deterioration (risk ratio [RR] = 0.83; 95% CI: 0.65-1.06, P = 0.14, I 2 = 29%), and hospitalization (RR = 0.80; 95% CI: 0.62-1.04, P = 0.09, I 2 = 0%) of Covid-19 outpatients. The serious adverse events did not differ significantly between the 2 groups. Conclusions and Relevance: This study indicates that although safe, fluvoxamine was not effective for outpatient treatment of Covid-19. Until more evidence can be obtained from larger RCTs, our study did not encourage the use of fluvoxamine as routine management for patients with Covid-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansFluvoxamineOutpatientsCOVID-19 Drug TreatmentEurope

Stichwörter der Autor:innen

Covid-19SARS-CoV-2SSRIcoronavirus disease 2019fluvoxaminemanagement

Substanzen

Fluvoxamine

Autor:innen und Institutionen

  • Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia.
  • Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Tangerang, Indonesia.

ORCID-Profile: Timotius Ivan Hariyanto

Zitieren

APA

Vatvani, A. D., Kurniawan, A., & Hariyanto, T. I. (2023). Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231162243

Vancouver

Vatvani AD, Kurniawan A, Hariyanto TI. Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials. Annals of Pharmacotherapy. 2023. doi:10.1177/10600280231162243

BibTeX
@article{Vatvani2023,
  author = {Vatvani, Akhil Deepak and Kurniawan, Andree and Hariyanto, Timotius Ivan},
  title = {Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials},
  journal = {Annals of Pharmacotherapy},
  year = {2023},
  doi = {10.1177/10600280231162243}
}
Kostenlos starten →